HK Stock Market Move | IMMUNEONCO-B(01541) opens more than 3% higher, and the first patient in the IMM2510 combination chemotherapy clinical trial has been dosed.

IMMUNEONCO-B (01541) opened more than 3% higher, rising by 3.7% to 4.77 Hong Kong dollars by the time of reporting, with a turnover of 387,300 Hong Kong dollars. In terms of news, IMMUNEONCO-B announced that the Ib/II phase clinical trial of IMM2510 in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has successfully dosed the first patient. After the safety induction period, the company plans to recruit first-line patients in the above-mentioned clinical trial, with preliminary clinical data expected to be released as early as the second half of 2025, including data from first-line NSCLC patients. According to reports, clinical data from the Phase I dose-escalation study of IMM2510 showed promising signs of efficacy: several advanced solid tumor patients who had failed multiple therapies achieved partial responses (PR) after receiving IMM2510 treatment. As of December 31, 2024, over 100 patients have been recruited for the Phase I/II clinical trial of IMM2510 monotherapy. Good tolerability and promising preliminary PR signals were observed in various solid tumor indications (including NSCLC, triple-negative breast cancer (TNBC), and soft tissue sarcoma (STS) patients who had failed previous treatments).